Home DailyMed 2afec18e-a0c8-4fc1-95a7-eaf2b3771e9b National Council for Prescription Drug Programs indexing - billing unit Drug label information. FDA.report displays public Structured Product Labeling data from DailyMed and legacy FDA.report DailyMed cache rows. This page is not medical advice, prescribing advice, or a substitute for the official label reviewed by a qualified healthcare professional. Labeling can change; when a current hydrated DailyMed SPL record is available, FDA.report shows that newer record before legacy cached files.
Manufacturer National Council for Prescription Drug Programs
Effective date 2012-07-24
Label type Indexing - Billing Unit
Version 1
Source full-release
Hydrated at 2026-06-05 01:25:01
Orange Book application contexts# All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
Orange Book application contexts page 1 of 1 · 1 matching rows.
Source provenance: Browse the complete Orange Book source catalog · source snapshot 44 .
Orange Book products# Current product rows page 1 of 1 · 2 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N022145-001 ISENTRESS RALTEGRAVIR POTASSIUM EQ 400MG BASE TABLET / ORAL AB RLD, RS 2007-10-12 N022145-002 ISENTRESS HD RALTEGRAVIR POTASSIUM EQ 600MG BASE TABLET / ORAL AB RLD, RS 2017-05-26
Therapeutic equivalence codes# Current TE-code rows page 1 of 1 · 2 matching rows.
Orange Book patents# Current patent rows page 1 of 1 · 10 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N022145-001 8852632 2028-01-28 U-257 Drug substance, Drug product 2023-03-27 N022145-001 7754731 2029-03-11 U-257 Drug substance, Drug product N022145-001 7754731*PED 2029-09-11 Pediatric extension N022145-001 8771733 2030-06-02 U-257 Drug substance, Drug product 2023-03-27 N022145-002 7754731 2029-03-11 U-257 Drug substance, Drug product 2017-06-23 N022145-002 7754731*PED 2029-09-11 Pediatric extension N022145-002 8771733 2030-06-02 U-257 Drug substance, Drug product 2023-03-27 N022145-002 9649311 2030-10-21 Drug product 2017-06-23 N022145-002 9649311*PED 2031-04-21 Pediatric extension N022145-002 10772888 2032-03-30 U-1663 2020-10-27
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 1 of 3 · 88 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-10-15 13:18:30 2026-09 N022145-001 ISENTRESS EQ 400MG BASE TABLET / ORAL AB RLD, RS 2007-10-12 c2088c7a36db…2026-10-15 13:18:30 2026-09 N022145-002 ISENTRESS HD EQ 600MG BASE TABLET / ORAL AB RLD, RS 2017-05-26 c2088c7a36db…2026-09-14 22:38:34 2026-08 N022145-001 ISENTRESS EQ 400MG BASE TABLET / ORAL AB RLD, RS 2007-10-12 84e616aacf4f…2026-09-14 22:38:34 2026-08 N022145-002 ISENTRESS HD EQ 600MG BASE TABLET / ORAL AB RLD, RS 2017-05-26 84e616aacf4f…2026-08-18 06:07:40 2026-07 N022145-001 ISENTRESS EQ 400MG BASE TABLET / ORAL RLD, RS 2007-10-12 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N022145-002 ISENTRESS HD EQ 600MG BASE TABLET / ORAL AB RLD, RS 2017-05-26 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N022145-001 ISENTRESS EQ 400MG BASE TABLET / ORAL RLD, RS 2007-10-12 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N022145-002 ISENTRESS HD EQ 600MG BASE TABLET / ORAL AB RLD, RS 2017-05-26 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N022145-001 ISENTRESS EQ 400MG BASE TABLET / ORAL RLD, RS 2007-10-12 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N022145-002 ISENTRESS HD EQ 600MG BASE TABLET / ORAL AB RLD, RS 2017-05-26 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N022145-001 ISENTRESS EQ 400MG BASE TABLET / ORAL RLD, RS 2007-10-12 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N022145-002 ISENTRESS HD EQ 600MG BASE TABLET / ORAL AB RLD, RS 2017-05-26 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N022145-001 ISENTRESS EQ 400MG BASE TABLET / ORAL RLD, RS 2007-10-12 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N022145-002 ISENTRESS HD EQ 600MG BASE TABLET / ORAL RLD, RS 2017-05-26 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N022145-001 ISENTRESS EQ 400MG BASE TABLET / ORAL RLD, RS 2007-10-12 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N022145-002 ISENTRESS HD EQ 600MG BASE TABLET / ORAL RLD, RS 2017-05-26 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N022145-001 ISENTRESS EQ 400MG BASE TABLET / ORAL AB RLD, RS 2007-10-12 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N022145-002 ISENTRESS HD EQ 600MG BASE TABLET / ORAL RLD, RS 2017-05-26 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N022145-001 ISENTRESS EQ 400MG BASE TABLET / ORAL RLD, RS 2007-10-12 2680178bc6a6…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N022145-002 ISENTRESS HD EQ 600MG BASE TABLET / ORAL RLD, RS 2017-05-26 2680178bc6a6…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N022145-001 ISENTRESS EQ 400MG BASE TABLET / ORAL RLD, RS 2007-10-12 5bbf6a4d5a75…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N022145-002 ISENTRESS HD EQ 600MG BASE TABLET / ORAL RLD, RS 2017-05-26 5bbf6a4d5a75…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N022145-001 ISENTRESS EQ 400MG BASE TABLET / ORAL RLD, RS 2007-10-12 d8e5a09893c0…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N022145-002 ISENTRESS HD EQ 600MG BASE TABLET / ORAL RLD, RS 2017-05-26 d8e5a09893c0…2024-10-29 15:01 UTC 2024-10 N022145-001 ISENTRESS EQ 400MG BASE TABLET / ORAL RLD, RS 2007-10-12 d06236e962d9…2024-10-29 15:01 UTC 2024-10 N022145-002 ISENTRESS HD EQ 600MG BASE TABLET / ORAL RLD, RS 2017-05-26 d06236e962d9…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N022145-001 ISENTRESS EQ 400MG BASE TABLET / ORAL RLD, RS 2007-10-12 79d66fd596c7…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N022145-002 ISENTRESS HD EQ 600MG BASE TABLET / ORAL RLD, RS 2017-05-26 79d66fd596c7…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 N022145-001 ISENTRESS EQ 400MG BASE TABLET / ORAL RLD, RS 2007-10-12 301d65b070ca…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 N022145-002 ISENTRESS HD EQ 600MG BASE TABLET / ORAL RLD, RS 2017-05-26 301d65b070ca…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 N022145-001 ISENTRESS EQ 400MG BASE TABLET / ORAL RLD, RS 2007-10-12 1e350fbaab3a…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 N022145-002 ISENTRESS HD EQ 600MG BASE TABLET / ORAL RLD, RS 2017-05-26 1e350fbaab3a…2024-05-31 18:47 UTC 2024-05 N022145-001 ISENTRESS EQ 400MG BASE TABLET / ORAL RLD, RS 2007-10-12 8072bd15b7f6…2024-05-31 18:47 UTC 2024-05 N022145-002 ISENTRESS HD EQ 600MG BASE TABLET / ORAL RLD, RS 2017-05-26 8072bd15b7f6…2022-06-29 02:47 UTC · 2 captures of this ZIP 2022-06 N022145-001 ISENTRESS EQ 400MG BASE TABLET / ORAL RLD, RS 2007-10-12 5c6f7cd8ea54…2022-06-29 02:47 UTC · 2 captures of this ZIP 2022-06 N022145-002 ISENTRESS HD EQ 600MG BASE TABLET / ORAL RLD, RS 2017-05-26 5c6f7cd8ea54…2022-04-08 23:34 UTC 2022-04 N022145-001 ISENTRESS EQ 400MG BASE TABLET / ORAL RLD, RS 2007-10-12 5d02ea3f76ae…2022-04-08 23:34 UTC 2022-04 N022145-002 ISENTRESS HD EQ 600MG BASE TABLET / ORAL RLD, RS 2017-05-26 5d02ea3f76ae…2022-04-04 05:41 UTC 2022-04 N022145-001 ISENTRESS EQ 400MG BASE TABLET / ORAL RLD, RS 2007-10-12 4b0b4de00fa7…2022-04-04 05:41 UTC 2022-04 N022145-002 ISENTRESS HD EQ 600MG BASE TABLET / ORAL RLD, RS 2017-05-26 4b0b4de00fa7…
Observed Orange Book normalized TE history# Observed Orange Book patent history# Patent history page 1 of 18 · 704 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-10-15 13:18:30 2026-09 N022145-001 8852632 2028-01-28 U-257 Drug substance, Drug product 2023-03-27 c2088c7a36db…2026-10-15 13:18:30 2026-09 N022145-001 7754731 2029-03-11 U-257 Drug substance, Drug product c2088c7a36db…2026-10-15 13:18:30 2026-09 N022145-001 7754731*PED 2029-09-11 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N022145-001 8771733 2030-06-02 U-257 Drug substance, Drug product 2023-03-27 c2088c7a36db…2026-10-15 13:18:30 2026-09 N022145-002 7754731 2029-03-11 U-257 Drug substance, Drug product 2017-06-23 c2088c7a36db…2026-10-15 13:18:30 2026-09 N022145-002 7754731*PED 2029-09-11 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N022145-002 8771733 2030-06-02 U-257 Drug substance, Drug product 2023-03-27 c2088c7a36db…2026-10-15 13:18:30 2026-09 N022145-002 9649311 2030-10-21 Drug product 2017-06-23 c2088c7a36db…2026-10-15 13:18:30 2026-09 N022145-002 9649311*PED 2031-04-21 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N022145-002 10772888 2032-03-30 U-1663 2020-10-27 c2088c7a36db…2026-09-14 22:38:34 2026-08 N022145-001 8852632 2028-01-28 U-257 Drug substance, Drug product 2023-03-27 84e616aacf4f…2026-09-14 22:38:34 2026-08 N022145-001 7754731 2029-03-11 U-257 Drug substance, Drug product 84e616aacf4f…2026-09-14 22:38:34 2026-08 N022145-001 7754731*PED 2029-09-11 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N022145-001 8771733 2030-06-02 U-257 Drug substance, Drug product 2023-03-27 84e616aacf4f…2026-09-14 22:38:34 2026-08 N022145-002 7754731 2029-03-11 U-257 Drug substance, Drug product 2017-06-23 84e616aacf4f…2026-09-14 22:38:34 2026-08 N022145-002 7754731*PED 2029-09-11 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N022145-002 8771733 2030-06-02 U-257 Drug substance, Drug product 2023-03-27 84e616aacf4f…2026-09-14 22:38:34 2026-08 N022145-002 9649311 2030-10-21 Drug product 2017-06-23 84e616aacf4f…2026-09-14 22:38:34 2026-08 N022145-002 9649311*PED 2031-04-21 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N022145-002 10772888 2032-03-30 U-1663 2020-10-27 84e616aacf4f…2026-08-18 06:07:40 2026-07 N022145-001 8852632 2028-01-28 U-257 Drug substance, Drug product 2023-03-27 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N022145-001 7754731 2029-03-11 U-257 Drug substance, Drug product caaa826d4ba7…2026-08-18 06:07:40 2026-07 N022145-001 7754731*PED 2029-09-11 Pediatric extension caaa826d4ba7…2026-08-18 06:07:40 2026-07 N022145-001 8771733 2030-06-02 U-257 Drug substance, Drug product 2023-03-27 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N022145-002 7754731 2029-03-11 U-257 Drug substance, Drug product 2017-06-23 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N022145-002 7754731*PED 2029-09-11 Pediatric extension caaa826d4ba7…2026-08-18 06:07:40 2026-07 N022145-002 8771733 2030-06-02 U-257 Drug substance, Drug product 2023-03-27 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N022145-002 9649311 2030-10-21 Drug product 2017-06-23 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N022145-002 9649311*PED 2031-04-21 Pediatric extension caaa826d4ba7…2026-08-18 06:07:40 2026-07 N022145-002 10772888 2032-03-30 U-1663 2020-10-27 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N022145-001 8852632 2028-01-28 U-257 Drug substance, Drug product 2023-03-27 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N022145-001 7754731 2029-03-11 U-257 Drug substance, Drug product 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N022145-001 7754731*PED 2029-09-11 Pediatric extension 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N022145-001 8771733 2030-06-02 U-257 Drug substance, Drug product 2023-03-27 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N022145-002 7754731 2029-03-11 U-257 Drug substance, Drug product 2017-06-23 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N022145-002 7754731*PED 2029-09-11 Pediatric extension 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N022145-002 8771733 2030-06-02 U-257 Drug substance, Drug product 2023-03-27 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N022145-002 9649311 2030-10-21 Drug product 2017-06-23 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N022145-002 9649311*PED 2031-04-21 Pediatric extension 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N022145-002 10772888 2032-03-30 U-1663 2020-10-27 011fe1cb6892…
Observed Orange Book exclusivity history# Exclusivity history page 1 of 2 · 54 observed states.
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.